
    
      This is a randomized double blind parallel clinical trial where hypertensive patients with
      controlled or uncontrolled blood pressure and without evidence of target-organ damage will be
      selected. Subjects will receive Simvastatin 40 mg once daily or placebo and a baseline and
      eight weeks ABPM will performed. The main outcome will be the difference in systolic BP in
      the 24h-ABPM.
    
  